Studies in rodent models found that overexpression of hepatic DGAT [66], blockade of hepatic VLDL secretion [67], and pharmacological blockade of beta-oxidation [68] cause hepatic steatosis but do not impair insulin action; conversely, inhibition of IHTG synthesis ameliorates hepatic steatosis but does not improve insulin action [69]. The gene discussed is INS; the disease is fatty liver disease.